Mikrogen T-Track SARS-CoV-2 Assay
Mikrogen, a Neuried, Germany-based developer of genetically manufactured in vitro diagnostics, has introduced its research-use-only T-Track SARS-CoV-2 assay to determine T-cell-mediated immune responses. The new RT-qPCR assays detect the mRNA expression of several specific marker cytokines simultaneously. The assays require about 3 ml of heparin blood/patient, are conducive to partial automation and intermediate storage of samples, and have shown a high sensitivity in the early infection phase, the company said.